Sarepta Therapeutics (NASDAQ:SRPT)‘s stock had its “hold” rating reaffirmed by research analysts at Credit Suisse Group in a report released on Monday. They presently have a $81.00 price objective on the biotechnology company’s stock. Credit Suisse Group’s target price suggests a potential upside of 2.40% from the company’s previous close.
SRPT has been the topic of a number of other reports. Janney Montgomery Scott initiated coverage on Sarepta Therapeutics in a research note on Wednesday, January 3rd. They issued a “buy” rating and a $75.00 target price on the stock. Morgan Stanley upped their target price on Sarepta Therapeutics from $63.00 to $64.00 and gave the stock an “overweight” rating in a research note on Tuesday, March 6th. BidaskClub upgraded Sarepta Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, December 25th. Piper Jaffray Companies restated an “overweight” rating on shares of Sarepta Therapeutics in a research note on Friday, March 2nd. Finally, Royal Bank of Canada initiated coverage on Sarepta Therapeutics in a research note on Monday, January 22nd. They issued an “outperform” rating on the stock. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and eighteen have given a buy rating to the company’s stock. Sarepta Therapeutics has a consensus rating of “Buy” and an average price target of $70.55.
Shares of Sarepta Therapeutics (NASDAQ SRPT) traded up $4.74 on Monday, reaching $79.10. The company had a trading volume of 2,785,699 shares, compared to its average volume of 1,460,000. The stock has a market cap of $5,110.00, a PE ratio of -98.88 and a beta of 1.51. The company has a debt-to-equity ratio of 0.54, a current ratio of 13.91 and a quick ratio of 12.96. Sarepta Therapeutics has a twelve month low of $28.14 and a twelve month high of $80.23.
Several institutional investors have recently made changes to their positions in the company. Xact Kapitalforvaltning AB bought a new position in shares of Sarepta Therapeutics during the 4th quarter valued at about $345,000. Handelsbanken Fonder AB bought a new position in Sarepta Therapeutics during the 4th quarter worth approximately $1,196,000. Delek Group Ltd. bought a new position in Sarepta Therapeutics during the 4th quarter worth approximately $2,056,000. Vanguard Capital Wealth Advisors bought a new position in Sarepta Therapeutics during the 4th quarter worth approximately $295,000. Finally, MetLife Investment Advisors LLC bought a new position in Sarepta Therapeutics during the 4th quarter worth approximately $1,538,000. Hedge funds and other institutional investors own 85.14% of the company’s stock.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.